Dupixent My Way - Search News

sBLA, Dupixent and Bullous Pemphigoid

SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application (sBLA) seeking approval for Dupixent for treating bullous pemphigoid (BP), a chronic,

Business Insider · 1d

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority

MarketWatch · 1d

Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions.

Regeneron, Sanofi announce Dupixent sBLA accepted for priority review by FDA

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...

FiercePharma12d

Regeneron tangles with Sanofi over commercial transparency in long-running Dupixent collaboration

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

pharmaphorum6y

FDA to review Sanofi's Dupixent in asthma

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

sBLA, Dupixent and Bullous Pemphigoid

Trending now